1. Renal Function and Myeloma Therapeutics

2. Objectives

4. Myeloma Clinical Features

5. Myeloma Renal Dysfunction at Diagnosis

6. Myeloma Renal Dysfunction at Diagnosis (cont)

7. Myeloma Renal Dysfunction at Diagnosis (cont)

8. Antimyeloma Agents in Renal Dysfunction

9. Treating Patients With Renal Impairment

10. Adjusting Therapy for End Organ Dysfunction

11. Bortezomib in Renal Dysfunction

12. Lenalidomide Starting Dose Adjustment for Renal Impairment

13. Cyclophosphamide

14. Cyclophosphamide (cont)

15. Bisphosphonates for Hypercalcemia

16. Bisphosphonates in Myeloma ASCO® Guidelines

17. 2007 ASCO® Guidelines

18. Bisphosphonate Infusion Duration

19. Renal Dysfunction

20. Carfilzomib in Renal Dysfunction

21. Carfilzomib in Renal Dysfunction

22. Pomalidomide in Renal Dysfunction

23. Emerging Agents

24. Summary

25. Questions and Answers

26. Abbreviations

27. Abbreviations (cont)

28. References

29. References (cont)

30. References (cont)

31. References (cont)

32. References (cont)

33. References (cont)

34. References (cont)